NL-OMON33901已完成不适用
A First in Human, Single-dose Escalation Study of LY2562175 In Healthy Subjects - LY2562175 single dose escalation study in humans
Chorus, Lilly Research Laboratories0 个研究点目标入组 18 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Healthy men or women of non child bearing potential
- •18 - 60 years inclusive
排除标准
- •18 - 60 years inclusive
- •BMI 18 - 30 kg/m
- •By screening no abnormalities found
研究者
相似试验
进行中（未招募）
1 期
A Phase 1, First-in-Human, Dose Escalation Study of the JNJ-75348780 Bispecific Antibody Targeting CD3 and CD22 in Participants with NHL and CRelapsed/refractory B-cell Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)CTIS2023-504403-92-00Janssen - Cilag International200
尚未招募
不适用
Phase 1, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants with Relapsed or Refractory Multiple Myelomamultiple myelomaNL-OMON53500Janssen-Cilag12
进行中（未招募）
1 期
A study of JNJ-79635322 in participants with relapsed or refractory multiple myeloma or previously treated amyloid light-chain (AL) amyloidosisRelapsed or refractory multiple myeloma or previously treated amyloid light-chain (AL) amyloidosisCancerISRCTN13185938Janssen Research & Development, LLC140
已完成
不适用
A First-in-Human Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Exploratory Markers of Efficacy for XAB05 in Healthy Subjects.treatment and the prevention of multidrug resistant (MDR) bacterial infections.10004018NL-OMON50582Xenothera SAS35
招募中
不适用
A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-219, an oral, covalent, menin inhibitor, in adult patients with acute leukemia (AL), diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM), and chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL)LeukemiaNL-OMON55976Biomea Fusion Inc.12